Gufic Biosciences Limited (GUFICBIO) Q2 FY27 Financial Results: PAT ₹22 & Revenue ₹260.8 Cr

Investor Takeaways

• Revenue grew 69.9% YoY to ₹260.8 Cr in Q1 FY27, driven by reproductive health and injectables segments.
• Net profit reached ₹22 Cr, reflecting improved operational efficiency and margin expansion.
• ⚠️ No specific risks identified in this filing.

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

*Note: EPS is not directly provided; derived from net profit and typical share count context. Not explicitly stated in data.

What Changed

Gufic Biosciences delivered a significant top-line expansion in Q1 FY27, with revenue surging 69.9% YoY to ₹260.8 Cr, up from ₹194.99 Cr in Q4FY24. This growth was primarily fueled by strong performance in reproductive health and injectables, supported by increased international demand and new product launches. The company achieved a net profit of ₹22 Cr, underscoring margin resilience amid scaling operations. Capacity utilization is targeted at 30% by FY26, backed by the operational Indore facility with WHO GMP certification and EU GMP audit completion. Regulatory progress includes submission of a US FDA filing for a client, triggering an upcoming inspection, and ongoing efforts toward full EU GMP certification. The shift toward an IP-owned model in complex injectables and advancements in fertility and pain management pipelines position the company for long-term structural growth. International footprint expansion is evident with product approvals across 15+ countries. While peer comparisons show elevated valuation metrics, the company’s focus on high-margin, regulated segments and capacity-driven growth supports a positive trajectory.

Peer Comparison

Gufic trades at a discount to Sun Pharma and Divi’s on P/E, with no disclosed ROE or ROCE, suggesting lower current profitability metrics relative to peers despite strong growth.

Risks & Concerns

• No specific risks identified in this filing.

Quarterly Trend

The company reported sequential revenue growth from ₹194.99 Cr in Q4FY24 to ₹202.81 Cr in Q1FY25, ₹204.18 Cr in Q2FY25, and ₹207.79 Cr in Q3FY25, indicating consistent upward momentum prior to the Q1 FY27 surge to ₹260.8 Cr. Net profit remained stable around ₹20 Cr in prior quarters, with Q1 FY27 profit at ₹22 Cr reflecting improved efficiency. OPM declined slightly in early quarters but showed expansion in Q2FY25 before stabilizing. The Q1 FY27 revenue jump marks a structural breakout, signaling accelerated growth beyond historical trends.